Amgen
Live price unavailable. Yahoo unofficial endpoint may be throttling or the ticker may be misconfigured.
loading 1-year chart…
1-year close · Yahoo Finance · daily interval
What they do in peptide space
Amgen's MariTide (formerly AMG 133, maridebart cafraglutide) is a monthly GIP-receptor antagonist + GLP-1 receptor agonist conjugate. Phase 2 data showed weight loss in the 14-20% range at 52 weeks with monthly dosing — meaningful both for the dosing convenience (vs weekly Wegovy/Zepbound) and for the durability of the loss curve.
MariTide differs mechanistically from tirzepatide in that it antagonizes GIP rather than agonizing it. The clinical reasoning is contested: some evidence suggests GIP antagonism produces effects similar to GIP agonism in the obesity context (the receptor desensitization story), while other interpretations argue the two should produce divergent metabolic responses. Phase 3 readouts in 2026-2027 will resolve this.
Amgen is also the manufacturer of Repatha (evolocumab, a monoclonal antibody) and Tepezza (teprotumumab) — peptide-adjacent biologics rather than small peptides, but illustrative of Amgen's biologics-platform strength.
Recent mentions
Coming soon — no editorial coverage or FDA alert mentioning Amgen in our index yet. Items will surface here as the news / FDA cron pipelines ingest them.